SIKA EXPANDS PRESENCE IN ECUADOR WITH A NEW PLANT
SIKA EXPANDS PRESENCE IN ECUADOR WITH A NEW PLANT
With the opening of the new plant in Quito, Sika further strengthens its presence and proximity to customers in Ecuador. This strategic investment enhances Sika's ability to tap into Ecuador's full market potential for its mortar solutions, which will be primarily used for interior walls and tile adhesives.
Sika already operates a mortar production facility in southern Ecuador, in the economic area of Guayaquil, the largest city in the country. Up until now, the Quito region in the north has been supplied from this location. With the new plant in Quito, Sika will optimize its nationwide supply chain with shorter transportation routes to serve customers more efficiently and reduce the carbon footprint.
Sika is well known in Ecuador and around the world for its innovative and high-performance solutions for the construction industry. Having been locally present in the country since many decades, Sika is a trusted partner to customers in all market segments. The presence and product offering for tile adhesives were significantly strengthened by the acquisition of Parex in 2019 and since then, Sika has built up a leading position for tile setting materials and mortars in Ecuador.
Mike Campion, Regional Manager Americas: 'Our new plant in Quito comes at a pivotal moment as Ecuador experiences a strong rebound in construction activity. Sika is well positioned to supply the growing markets in both the North and South of the country with high-quality, innovative solutions.'
After a three-year downturn, Ecuador's construction industry is poised for recovery, with an expected average annual growth rate of 4.3% up to 2028. This recovery will be driven by investment in mining, transportation, electricity infrastructure, as well as residential construction projects.
SIKA CORPORATE PROFILESika is a specialty chemicals company with a globally leading position in the development and production of systems and products for bonding, sealing, damping, reinforcing, and protection in the building sector and industry. Sika has subsidiaries in 102 countries around the world, produces in over 400 factories, and develops innovative technologies for customers worldwide. In doing so, it plays a crucial role in enabling the transformation of the construction and transportation industries toward greater environmental compatibility. Its 34,000 or so employees generated annual sales of CHF 11.76 billion in 2024.
CONTACTDominik SlappnigCorporate Communications &Investor Relations+41 58 436 68 21slappnig.dominik@ch.sika.com
The media release can be downloaded from the following link:Media Release.pdf
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement
Shares of Dishman Carbogen Amcis Ltd. could see increased investor interest after its Swiss subsidiary, CARBOGEN AMCIS AG, announced a strategic co-investment exceeding CHF 25 million with a key Japanese client. The deal is aimed at expanding antibody-drug conjugate (ADC) manufacturing capabilities at the company's Aarau and Neuland sites in Switzerland. The investment will specifically support the production of a drug linker used in commercial ADCs, an area witnessing rising global demand. Under the agreement, both sites will undergo significant upgrades: Aarau will see the installation of 850-litre reactors and agitated filter dryers by Q1 2027, while similar enhancements at Neuland are scheduled for completion by Q3 2027. This development marks the second major collaboration between CARBOGEN AMCIS and the same customer, building on a 2021 joint funding project for the Bubendorf site. The announcement reaffirms the company's growing importance in handling complex, high-potency APIs and delivering end-to-end CDMO (Contract Development and Manufacturing Organization) services across global markets. Given the scale and strategic nature of this co-investment, the move is expected to bolster Dishman Carbogen's long-term growth outlook and may reflect positively in its stock performance in the coming sessions. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Yahoo
2 days ago
- Yahoo
Idorsia publishes invitations to bondholder meetings
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and CB 2028 Allschwil, Switzerland – June 6, 2025Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period for the amended terms approved at the CB 2025 bondholder meeting of February 25, 2025 – during which no appeal was filed – it has published invitations to the next bondholder meetings for holders of its outstanding CHF 200 million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079). At the meetings, the company will propose changing the current terms of the CB 2025 and CB 2028 as part of the larger holistic restructuring, as announced in a press release on February 26, 2025, and an update published on May 21, 2025. To date, approximately 87% of the holders of the CB 2025 and 90% of holders of the CB 2028 have entered a legally binding lockup agreement in support of the holistic restructuring. Such bondholders have committed to vote in favour of the proposed amendments to the terms of the CB 2025 and CB 2028 at or before the meeting. The amendment of the terms of the CB 2025 and CB 2028 will be conditional on the consummation of the exchange offer, which is expected to be launched around or following the date of the bondholder meetings. Bondholders can access the invitations to the two bondholder meetings scheduled for Wednesday, June 25, 2025, including the terms of the resolution and additional information about the meeting, as well as a financial status report as of April 30, 2025, at the following links: and Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 – – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF
Yahoo
3 days ago
- Yahoo
Oculis Publishes Results of 2025 Annual General Meeting
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ('Oculis' or the 'Company'), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company's shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incurred a loss of CHF 5,179,000 with respect to the financial year ended December 31, 2024, and resolved that the accumulated balance sheet loss of CHF 46,577,000 shall be carried forward to the new accounts. The members of the Board of Directors and the Executive Committee were granted discharge for their activities in 2024. Anthony Rosenberg was re-elected as member and chairperson of the Board of Directors. Christina Ackermann, Lionel Carnot, Arshad M. Khanani, Martijn Kleijwegt, Geraldine O'Keeffe, Riad Sherif and Robert K. Warner were re-elected as members of the Board of Directors. Christina Ackermann, Lionel Carnot and Robert K. Warner were re-elected as members of the Compensation Committee. PricewaterhouseCoopers SA (Pully) was re-elected as Statutory Auditors. PST Legal AG (Zug) was re-elected as Independent Proxy. The shareholders approved the compensation for the non-executive members of the Board of Directors: Total maximum amount of fixed (non-performance-related) compensation for the non-executive members of the Board of Directors until the end of the Company's 2026 Annual General Meeting: USD 572,000. Maximum value of equity or equity-based compensation for eight non-executive members of the Board of Directors until the end of the Company's 2026 Annual General Meeting: USD 2,150,000 (excluding employer social security and pension contributions). The shareholders approved the compensation for members of the Executive Committee: Total maximum amount of fixed (non-performance-related) compensation for three members of the Executive Committee for the calendar year 2026 and payable in 2026: USD 2,478,240. Total maximum amount of variable compensation for three members of the Executive Committee for the calendar year 2025 and payable in 2026 of USD 1,753,760. Maximum value of equity-based compensation for three members of the Executive Committee until the end of the calendar year 2026: USD 15,500,000 (excluding employer social security and pension contributions). The shareholders approved, in a non-binding advisory vote, the 2024 Compensation Report of the Company. The shareholders approved a capital band of 27,266,837 registered shares resulting in a capital band between CHF 545,336.74 and CHF 818,005.11 and the related amendment of the paragraphs 1 through 3 of article 3a of the articles of association in the form published on the website of the Company at The shareholders approved a conditional share capital for employees and individuals of comparable positions in the maximum amount of CHF 124,800 by the issuance of 12,480,000 registered shares and the related amendment of article 3c, paragraph 1 of the articles of association in the form published on the website of the Company at About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS / XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis' highly differentiated pipeline of multiple innovative product candidates in clinical development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: Oculis Contacts Ms. Sylvia Cheung, CFO Investor Relations LifeSci Advisors Corey Davis, Ph.D. cdavis@ Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous oculis@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
